Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 5fludarabine phosphate 3Methotrexate 3venetoclax 2merphos 2fludarabine 2Whole-Body Irradiation 2Thiotepa 2Tacrolimus 2Rituximab 2Mycophenolic Acid 2tagraxofusp 1prednylidene 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1azathiopurine 1auricularum 1Vincristine 1Sirolimus 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Methylprednisolone 1Mesna 1Mercaptopurine 1Medrol Veriderm 1Injections 1Doxorubicin 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blastic Plasmacytoid Dendritic Cell Neoplasm × tagraxofusp × 90 days × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡